Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

WHI and aftermath: looking beyond the figures.

Amos Pines1

  • 1Department of Medicine T, Ichilov Medical Center, Tel-Aviv, and the Menopause Clinic, Ramat-Marpe, Ramat-Gan, 6 Weizman Street, Tel-Aviv 64239, Israel. apines@netvision.net.il

Maturitas
|May 11, 2005
PubMed
Summary

Final results from the Women's Health Initiative (WHI) hormone therapy trials suggest that concerns about hormone treatment for menopausal women were overstated. Data indicates safety for younger women, challenging previous assumptions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recommended measurement instruments for menopausal vasomotor symptoms: the COMMA (Core Outcomes in Menopause) consortium.

Menopause (New York, N.Y.)·2024
Same author

Lessons from shaking menopausal hands.

Menopause (New York, N.Y.)·2022
Same author

Global consensus recommendations on menopause in the workplace: A European Menopause and Andropause Society (EMAS) position statement.

Maturitas·2021
Same author

Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide.

Maturitas·2021
Same author

Management of urinary incontinence in postmenopausal women: An EMAS clinical guide.

Maturitas·2020
Same author

The Mediterranean diet and menopausal health: An EMAS position statement.

Maturitas·2020

Area of Science:

  • Reproductive Endocrinology
  • Women's Health
  • Clinical Trials

Background:

  • The Women's Health Initiative (WHI) initially studied hormone therapy in elderly women for cardioprotection.
  • Preliminary WHI results on conjugated equine estrogen (CEE) plus medroxyprogesterone acetate (MPA) raised safety concerns.
  • Previous interpretations led to widespread apprehension regarding hormone therapy for menopausal symptom management.

Purpose of the Study:

  • To re-evaluate the safety and efficacy of hormone therapy for menopausal women based on updated WHI data.
  • To assess the implications of final WHI results, including CEE-only therapy, for current clinical practice.
  • To provide a more nuanced understanding of hormone therapy risks and benefits, particularly for younger menopausal populations.

Main Methods:

Related Experiment Videos

  • Analysis of final results from the WHI CEE plus MPA arm.
  • Review of preliminary data from the WHI CEE-only arm.
  • Stratification of data analysis by age, focusing on women younger than 60 years.

Main Results:

  • Final WHI data indicates that the initial panic over hormone therapy was largely unjustified.
  • Preliminary data from the CEE-only arm also suggests a more favorable safety profile.
  • Results for women under 60 years old were particularly reassuring, showing minimal risks.

Conclusions:

  • The WHI findings should not be generalized to all menopausal women, especially younger symptomatic individuals.
  • Hormone therapy can be considered a beneficial option for symptomatic perimenopausal and early post-menopausal women.
  • Current evidence supports reconsidering restrictive policies on hormone therapy for appropriate patient populations.